Jia-Cheng Lu,Lei-Lei Wu,Yi-Ning Sun,Xiao-Yong Huang,Chao Gao,Xiao-Jun Guo,Hai-Ying Zeng,Xu-Dong Qu,Yi Chen,Dong Wu,Yan-Zi Pei,Xian-Long Meng,Yi-Min Zheng,Chen Liang,Peng-Fei Zhang,Jia-Bin Cai,Zhen-Bin Ding,Guo-Huan Yang,Ning Ren,Cheng Huang,Xiao-Ying Wang,Qiang Gao,Qi-Man Sun,Ying-Hong Shi,Shuang-Jian Qiu,Ai-Wu Ke,Guo-Ming Shi,Jian Zhou,Yi-Di Sun,Jia Fan

Abstract:Abstract Intratumoral immune status influences tumor therapeutic response, but it remains largely unclear how the status determines therapies for patients with intrahepatic cholangiocarcinoma. Here, we examine the single-cell transcriptional and TCR profiles of 18 tumor tissues pre- and post- therapy of gemcitabine plus oxaliplatin, in combination with lenvatinib and anti-PD1 antibody for intrahepatic cholangiocarcinoma. We find that high CD8 GZMB + and CD8 proliferating proportions and a low Macro CD5L + proportion predict good response to the therapy. In patients with a poor response, the CD8 GZMB + and CD8 proliferating proportions are increased, but the CD8 GZMK + proportion is decreased after the therapy. Transition of CD8 proliferating and CD8 GZMB + to CD8 GZMK + facilitates good response to the therapy, while Macro CD5L + –CD8 GZMB + crosstalk impairs the response by increasing CTLA4 in CD8 GZMB + . Anti-CTLA4 antibody reverses resistance of the therapy in intrahepatic cholangiocarcinoma. Our data provide a resource for predicting response of the combination therapy and highlight the importance of CD8 + T-cell status conversion and exhaustion induced by Macro CD5L + in influencing the response, suggesting future avenues for cancer treatment optimization.

Macro CD5L+ deteriorates CD8+T cells exhaustion and impairs combination of Gemcitabine-Oxaliplatin-Lenvatinib-anti-PD1 therapy in intrahepatic cholangiocarcinoma